Introduction: Atrial fibrillation (AF) is the most common cardiac arrhythmia with significant
morbidity and mortality in relation to thromboembolic stroke. Our study aimed to evaluate the …

Background Little is known about the clinical benefit of a non–vitamin K antagonist oral
anticoagulant compared with warfarin in elderly Chinese patients with atrial fibrillation (AF) …

Background: The Asian population with atrial fibrillation (AF) have a higher risk of stroke
than the caucasian population and a higher risk of intracranial bleeding when …

Objective: To evaluate the safety and efficacy of dabigatran for stroke prevention in the
elderly population. Data Sources: MEDLINE (1948-June 2013), Web of Science (1980-June …

Background: Dabigatran is an oral direct thrombin inhibitor recently approved for stroke
prevention in atrial fibrillation (AF) as an alternative to warfarin. The primary advantages of …

Objective The prevalence of atrial fibrillation (AF) and the risk of stroke and bleeding vary
according to age. To estimate effects of dabigatran, compared with warfarin, on stroke …

Background Dabigatran, an oral direct thrombin inhibitor, possesses several advantages
over warfarin that can in principle simplify the management of stroke prevention in atrial …

Objective: This analysis was performed to evaluate the efficacy in stroke prevention and
safety of dabigatran in Chinese nonvalvular atrial fibrillation (NVAF) patients enrolled in RE …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are approved
for stroke prevention in atrial fibrillation (AF) patients, their use in the local clinical setting has …

The elderly with atrial fibrillation are more prone to stroke. Oral anticoagulants such as
warfarin are effective in the prevention of atrial fibrillation–associated stroke and systemic …